Shore Capital view: Creo Medical (‘CREO’) is at a commercial inflection point. In FY25, sales of its surgical endoscopy tools grew substantially (+50%) despite a tightening cost base (-20%), establishing that
Shore Capital view: Creo Medical (‘CREO’) is at a commercial inflection point. In FY25, sales of its surgical endoscopy tools grew substantially (+50%) despite a tightening cost base (-20%), establishing that
Yesterday Kavango Resources (KAV) advised that Mr Ben Turney is leaving his position as CEO, and as a Director of the Company, with immediate effect. Mr Peter Wynter Bee, Executive Chairman will
Lift Global Ventures (AQSE:LFT), an investment company focused on financial media, technology, and related sectors, announced it will invest in artificial intelligence (“AI”) as part of its existing investment policy.
Ocado is at risk of being removed from the FTSE 100 due to a significant drop in its share price, increasing pressure on the company to consider relocating from London